What are the latest figures on the colorectal cancer screening market’s size and projected CAGR?
The colorectal cancer screening market size has grown strongly in recent years. It will grow from $15.61 billion in 2024 to $16.6 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to the increasing incidence of colorectal cancer, rising government awareness campaigns, an aging population, growing adoption of colonoscopy, and improved insurance coverage.
The colorectal cancer screening market size is expected to see strong growth in the next few years. It will grow to $21.01 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to a shift to non-invasive screening methods, increasing home-based screening tests, growing prevalence of obesity, rising adoption of value-based healthcare, and increasing public-private partnerships. Major trends in the forecast period include the integration of AI in screening and diagnostics, expansion of screening guidelines to younger populations, broader use of genomic testing for cancer risk, growth in mobile health (mHealth) platforms, and collaborations between pharmaceutical and diagnostic companies.
Get Your Free Sample of The Global Colorectal Cancer Screening Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19008&type=smp
Which Market drivers have played a significant role in driving the colorectal cancer screening market?
The increasing aging population is expected to propel the growth of the colorectal cancer screening market going forward. An aging population refers to a demographic trend where the proportion of elderly individuals (typically 65 years and older) increases relative to the working-age population, often due to longer life expectancy and declining birth rates. The aging population is growing due to longer life expectancies and declining birth rates, leading to a higher proportion of older adults in the global population. Colorectal cancer screening is essential for managing the needs of the growing aging population by enabling early detection and preventive measures, which address the elevated cancer risk in older adults and enhance their overall health outcomes. For instance, in January 2024, according to the facts published by the Population Reference Bureau (PRB), a US-based nonprofit research organization, the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase, while their proportion of the total population is anticipated to grow from 17% to 23%. Therefore, the increasing aging population is driving the colorectal cancer screening market.
What are the key segments within the colorectal cancer screening market?
The colorectal cancer screeningmarket covered in this report is segmented –
1) By Type: Stool-Based, Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Stool Deoxyribonucleic Acid (DNA) Test, Colonoscopy, Other Types
2) By Age Group: Below 50 Years, 50-64 Years, Above 65 Years
3) By End User: Hospitals And Clinics, Clinical Laboratories, Diagnostic Imaging Centers, Other End-Users
Subsegments:
1) By Stool-Based Tests: Stool-Based Tests
2) By Fecal Immunochemical Test (FIT): High-Sensitivity FIT, Low-Sensitivity FIT
3) By Fecal Occult Blood Test (FOBT): Guaiac FOBT, Immunochemical FOBT
4) By Stool Deoxyribonucleic Acid (DNA) Test: Multi-Target Stool DNA Test, Single-Target Stool DNA Test
5) By Colonoscopy: Diagnostic Colonoscopy, Therapeutic Colonoscopy
6) By Other Types: Virtual Colonoscopy, Flexible Sigmoidoscopy, Capsule Endoscopy
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-screening-global-market-report
Which key players are shaping the colorectal cancer screening market?
Major companies operating in the colorectal cancer screening market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Siemens Healthineers, FUJIFILM Holdings Corporation, GE HealthCare, Boston Scientific Corporation, Olympus Corporation, Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., Eiken Chemical Co. Ltd., HemoCue AB, Clinical Genomics Inc., Polymedco LLC, Hemosure Inc., Geneoscopy Inc., Novigenix SA
Which transformative trends will shape the colorectal cancer screening market landscape?
Major companies operating in the colorectal cancer screening market are focusing on developing innovative solutions such as non-invasive multi-target stool ribonucleic acid (RNA) colorectal cancer screening tests to offer an accessible, effective method for early detection of colorectal cancer, improving patient outcomes, and encouraging broader screening participation. Non-invasive multi-target stool RNA colorectal cancer screening tests analyze RNA markers from a stool sample to detect the presence of colorectal cancer or precancerous lesions, offering a non-surgical method for early detection. For instance, in May 2024, Geneoscopy Inc., a US-based life sciences company, announced the U.S. Food and Drug Administration (FDA) approval of ColoSense. This uses RNA biomarkers for a non-invasive, stool-based screening that demonstrated 93% sensitivity for detecting colorectal cancer and 45% sensitivity for advanced adenomas. Its significance lies in its high accuracy, especially in younger populations, and its potential to increase screening rates by offering a less invasive alternative to traditional methods.
How do regional factors impact the colorectal cancer screening market, and which region is the largest contributor?
North America was the largest region in the colorectal cancer screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Colorectal Cancer Screening Market Report 2025 Offer?
The colorectal cancer screening market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Colorectal cancer screening involves testing to detect early signs of colorectal cancer before symptoms develop. Early detection through screening can identify precancerous polyps or cancer at a more treatable stage, significantly improving outcomes. Screening is recommended for adults starting at age 45 or earlier for those at higher risk.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19008
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
